Dna X annual operating margin
2018
2019
2020
2021
2022
2023
2024
Dna X's operating margin was −6.09% for fiscal 2024.
View full Dna X company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −6.09% | −6.64 pp |
| 2023 | 2023-12-31 | 0.55% | +21.01 pp |
| 2022 | 2022-12-31 | −20.46% | +49.17 pp |
| 2021 | 2021-12-31 | −69.64% | −23.91 pp |
| 2020 | 2020-12-31 | −45.72% | −26.47 pp |
| 2019 | 2019-12-31 | −19.25% | −23.23 pp |
| 2018 | 2018-12-31 | 3.98% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q3 2025 | 2025-09-30 | −24.55% | −8.73 pp |
| Q2 2025 | 2025-06-30 | −13.15% | +43.04 pp |
| Q1 2025 | 2025-03-31 | −5.20% | +24.29 pp |
| Q4 2024 | 2024-12-31 | 55.26% | +64.61 pp |
| Q3 2024 | 2024-09-30 | −15.82% | −18.31 pp |
| Q2 2024 | 2024-06-30 | −56.18% | −58.97 pp |
| Q1 2024 | 2024-03-31 | −29.49% | −30.78 pp |
| Q4 2023 | 2023-12-31 | −9.34% | −4.95 pp |
| Q3 2023 | 2023-09-30 | 2.50% | +11.91 pp |
| Q2 2023 | 2023-06-30 | 2.78% | +38.08 pp |
| Q1 2023 | 2023-03-31 | 1.29% | +54.71 pp |
| Q4 2022 | 2022-12-31 | −4.39% | +69.31 pp |
| Q3 2022 | 2022-09-30 | −9.41% | +64.82 pp |
| Q2 2022 | 2022-06-30 | −35.30% | +18.96 pp |
| Q1 2022 | 2022-03-31 | −53.42% | +20.52 pp |
| Q4 2021 | 2021-12-31 | −73.71% | −26.59 pp |
| Q3 2021 | 2021-09-30 | −74.23% | −31.72 pp |
| Q2 2021 | 2021-06-30 | −54.26% | −22.82 pp |
| Q1 2021 | 2021-03-31 | −73.94% | −2.63 pp |
| Q4 2020 | 2020-12-31 | −47.11% | −4.02 pp |
| Q3 2020 | 2020-09-30 | −42.51% | −20.82 pp |
| Q2 2020 | 2020-06-30 | −31.44% | −20.97 pp |
| Q1 2020 | 2020-03-31 | −71.31% | −55.67 pp |
| Q4 2019 | 2019-12-31 | −43.09% | −54.98 pp |
| Q3 2019 | 2019-09-30 | −21.69% | −30.01 pp |
| Q2 2019 | 2019-06-30 | −10.47% | −12.37 pp |
| Q1 2019 | 2019-03-31 | −15.64% | +6.43 pp |
| Q4 2018 | 2018-12-31 | 11.88% | — |
| Q3 2018 | 2018-09-30 | 8.31% | — |
| Q2 2018 | 2018-06-30 | 1.90% | — |
| Q1 2018 | 2018-03-31 | −22.07% | — |
Over the last five reported fiscal years, Dna X's operating margin increased from −19.25% to −6.09%, a change of +13.16 percentage points. The latest reported quarter, Q3 2025, shows −24.55%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dna X filings at SEC.gov ↗